Innovation in drug development has spread well beyond the confines of traditional biotechnology companies. As such, starting in 2016, we are making several important changes in the way we analyze the business and financial developments of the industry in BioWorld Today, BioWorld Insight and BioWorld Snapshots.
Deals: Since the 1980s, the biotech industry has rapidly evolved, blurring the lines between biotechnology and pharmaceutical companies due to massive mergers and acquisitions. Therefore, all of our deals and collaborations going forward will be grouped into one chart, including all companies working in the space, and organized by buyers and licensors as opposed to biotech and pharma companies.
Clinics: All charts detailing clinical trials will include all companies working in the space, rather than separating them as biotech or pharmaceutical.
Products: Products approved by the FDA will no longer be limited to conventional biotech companies, but will henceforth include all new molecular entities, biosimilars and biologics developed by all companies, categorized by their various pathways to market.
IPOs: Increasingly, foreign biopharma companies are listing on U.S. exchanges via American Depositary Shares. These companies, that file S-1s or F-1s with the SEC, will continue to be listed in our IPO charts but with an asterisk, and their totals will be separated from the traditional IPO totals tracked by BioWorld.
Stock report: Finally, the burgeoning biopharma industry, with its increasing number of IPOs, now necessitates that we limit our stock reporting to include only companies that are listed on U.S. exchanges. We will also discontinue BioWorld Today's daily stock movers chart but continue to publish a weekly stock movers chart in BioWorld Insight. That chart will reflect the stock movements of companies with a market cap greater than $250 million and a share price greater than $1.
The BioWorld staff wishes you a prosperous and happy 2016.